5485 related articles for article (PubMed ID: 24521777)
1. Acute rejection, T-cell-depleting antibodies, and cancer after transplantation.
Lim WH; Turner RM; Chapman JR; Ma MK; Webster AC; Craig JC; Wong G
Transplantation; 2014 Apr; 97(8):817-25. PubMed ID: 24521777
[TBL] [Abstract][Full Text] [Related]
2. Cumulative Doses of T-Cell Depleting Antibody and Cancer Risk after Kidney Transplantation.
Chen JH; Wong G; Chapman JR; Lim WH
PLoS One; 2015; 10(11):e0139479. PubMed ID: 26555791
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
[TBL] [Abstract][Full Text] [Related]
4. Transplantation. T-cell depletion--balancing acute rejection and cancer risk.
Reddy UG; Danovitch GM
Nat Rev Nephrol; 2014 Jun; 10(6):301-2. PubMed ID: 24709843
[TBL] [Abstract][Full Text] [Related]
5. T-cell-depleting antibodies and risk of cancer after transplantation.
Snanoudj R; Legendre C
Transplantation; 2014 Apr; 97(8):808-9. PubMed ID: 24670299
[No Abstract] [Full Text] [Related]
6. The risk of cancer in recipients of living-donor, standard and expanded criteria deceased donor kidney transplants: a registry analysis.
Ma MK; Lim WH; Turner RM; Chapman JR; Craig JC; Wong G
Transplantation; 2014 Dec; 98(12):1286-93. PubMed ID: 25119131
[TBL] [Abstract][Full Text] [Related]
7. Induction Therapy, Rejection, and Graft Outcomes in Pediatric and Adolescent Kidney Transplant Recipients.
Mincham CM; Wong G; Teixeira-Pinto A; Kennedy S; Alexander S; Larkins N; Lim WH
Transplantation; 2017 Sep; 101(9):2146-2151. PubMed ID: 28832451
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous melanoma is related to immune suppression in kidney transplant recipients.
Vajdic CM; van Leeuwen MT; Webster AC; McCredie MR; Stewart JH; Chapman JR; Amin J; McDonald SP; Grulich AE
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2297-303. PubMed ID: 19622722
[TBL] [Abstract][Full Text] [Related]
9. Kidney transplantation in hepatitis C-positive recipients: does type of induction influence outcomes?
Sureshkumar KK; Thai NL; Marcus RJ
Transplant Proc; 2012 Jun; 44(5):1262-4. PubMed ID: 22663997
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
[TBL] [Abstract][Full Text] [Related]
11. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
[TBL] [Abstract][Full Text] [Related]
12. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
Kasiske BL; Kukla A; Thomas D; Wood Ives J; Snyder JJ; Qiu Y; Peng Y; Dharnidharka VR; Israni AK
Am J Kidney Dis; 2011 Dec; 58(6):971-80. PubMed ID: 21930332
[TBL] [Abstract][Full Text] [Related]
13. Pre-transplant donor-specific T-cell alloreactivity is strongly associated with early acute cellular rejection in kidney transplant recipients not receiving T-cell depleting induction therapy.
Crespo E; Lucia M; Cruzado JM; Luque S; Melilli E; Manonelles A; Lloberas N; Torras J; Grinyó JM; Bestard O
PLoS One; 2015; 10(2):e0117618. PubMed ID: 25689405
[TBL] [Abstract][Full Text] [Related]
14. Assessing the risk of de novo malignancy in kidney transplant recipients: role for monitoring of peripheral blood lymphocyte populations.
Fernández-Ruiz M; López-Medrano F; Allende LM; Andrés A; Paz-Artal E; Aguado JM
Transplantation; 2014 Sep; 98(5):e36-7. PubMed ID: 25171527
[No Abstract] [Full Text] [Related]
15. Time on dialysis and cancer risk after kidney transplantation.
Wong G; Turner RM; Chapman JR; Howell M; Lim WH; Webster AC; Craig JC
Transplantation; 2013 Jan; 95(1):114-21. PubMed ID: 23222892
[TBL] [Abstract][Full Text] [Related]
16. Early versus late acute antibody-mediated rejection in renal transplant recipients.
Dörje C; Midtvedt K; Holdaas H; Naper C; Strøm EH; Øyen O; Leivestad T; Aronsen T; Jenssen T; Flaa-Johnsen L; Lindahl JP; Hartmann A; Reisæter AV
Transplantation; 2013 Jul; 96(1):79-84. PubMed ID: 23632391
[TBL] [Abstract][Full Text] [Related]
17. Cell-mediated and humoral acute vascular rejection and graft loss: A registry study.
Teo RZ; Wong G; Russ GR; Lim WH
Nephrology (Carlton); 2016 Feb; 21(2):147-55. PubMed ID: 26243593
[TBL] [Abstract][Full Text] [Related]
18. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
Laufer G; Miholic J; Laczkovics A; Wollenek G; Holzinger C; Hajek-Rosenmeier A; Wuzl G; Schreiner W; Buxbaum P; Wolner E
J Thorac Cardiovasc Surg; 1989 Dec; 98(6):1113-21. PubMed ID: 2586129
[TBL] [Abstract][Full Text] [Related]
19. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
Charlton M; Seaberg E
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S107-14. PubMed ID: 10431024
[TBL] [Abstract][Full Text] [Related]
20. Cancer-Specific and All-Cause Mortality in Kidney Transplant Recipients With and Without Previous Cancer.
Viecelli AK; Lim WH; Macaskill P; Chapman JR; Craig JC; Clayton P; Cohney S; Carroll R; Wong G
Transplantation; 2015 Dec; 99(12):2586-92. PubMed ID: 26102612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
